1. Cancer Biology

MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans

  1. Calvin VanOpstall
  2. Srikanth Perike
  3. Hannah Brechka
  4. Marc Gillard
  5. Sophia Lamperis
  6. Baizhen Zhu
  7. Ryan Brown
  8. Raj Bhanvadia
  9. Donald J Vander Griend  Is a corresponding author
  1. The University of Chicago, United States
  2. The University of Illinois at Chicago, United States
https://doi.org/10.7554/eLife.53600
Share this article
Cite this article
  1. Calvin VanOpstall
  2. Srikanth Perike
  3. Hannah Brechka
  4. Marc Gillard
  5. Sophia Lamperis
  6. Baizhen Zhu
  7. Ryan Brown
  8. Raj Bhanvadia
  9. Donald J Vander Griend
(2020)
MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans
eLife 9:e53600.
https://doi.org/10.7554/eLife.53600
  2. Download BibTeX
  3. Download .RIS

Abstract

The molecular roles of HOX transcriptional activity in human prostate epithelial cells remain unclear, impeding the implementation of new treatment strategies for cancer prevention and therapy. MEIS proteins are transcription factors that bind and direct HOX protein activity. MEIS proteins are putative tumor suppressors that are frequently silenced in aggressive forms of prostate cancer. Here we show that MEIS1 expression is sufficient to decrease proliferation and metastasis of prostate cancer cells in vitro and in vivo murine xenograft models. HOXB13 deletion demonstrates that the tumor-suppressive activity of MEIS1 is dependent on HOXB13. Integration of ChIP-seq and RNA-seq data revealed direct and HOXB13-dependent regulation of proteoglycans including decorin (DCN) as a mechanism of MEIS1-driven tumor suppression. These results define and underscore the importance of MEIS1-HOXB13 transcriptional regulation in suppressing prostate cancer progression and provide a mechanistic framework for the investigation of HOXB13 mutants and oncogenic cofactors when MEIS1/2 are silenced.

Data availability

RNA-seq and ChIP-seq raw and analyzed data have been deposited at the Gene Expression Omnibus and Sequence Read Archive under the accession number GSE132717.

The following previously published data sets were used

Article and author information

Author details

  1. Calvin VanOpstall

    Ben May Institute for Cancer Research, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Srikanth Perike

    Pathology, The University of Illinois at Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Hannah Brechka

    Surgery, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Marc Gillard

    Surgery, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Sophia Lamperis

    Pathology, The University of Illinois at Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Baizhen Zhu

    Surgery, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Ryan Brown

    Pathology, The University of Illinois at Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Raj Bhanvadia

    Pritzker School of Medicine, The University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Donald J Vander Griend

    Pathology, The University of Illinois at Chicago, Chicago, United States
    For correspondence
    dvanderg@uic.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4421-5698

Funding

U.S. Department of Defense (PC130587)

  • Donald J Vander Griend

U.S. Department of Defense (PC180414)

  • Donald J Vander Griend

National Institutes of Health (P50 CA180995)

  • Donald J Vander Griend

National Institutes of Health (T32 CA009594)

  • Calvin VanOpstall
  • Hannah Brechka
  • Donald J Vander Griend

National Institutes of Health (F31CA232651)

  • Calvin VanOpstall

National Institutes of Health (P30CA014599)

  • Donald J Vander Griend

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Wilbert Zwart, Netherlands Cancer Institute, Netherlands

Ethics

Animal experimentation: All animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the University of Chicago Institutional Animal Care and Use Committee (IACUC) (protocol #72231) as well as by the University of Illinois at Chicago IACUC (protocol #18-100).

Version history

  1. Received: November 14, 2019
  2. Accepted: June 17, 2020
  3. Accepted Manuscript published: June 18, 2020 (version 1)
  4. Version of Record published: July 20, 2020 (version 2)

Copyright

© 2020, VanOpstall et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 25,639
    views
  • 298
    downloads
  • 29
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Calvin VanOpstall
  2. Srikanth Perike
  3. Hannah Brechka
  4. Marc Gillard
  5. Sophia Lamperis
  6. Baizhen Zhu
  7. Ryan Brown
  8. Raj Bhanvadia
  9. Donald J Vander Griend
(2020)
MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans
eLife 9:e53600.
https://doi.org/10.7554/eLife.53600

Share this article

https://doi.org/10.7554/eLife.53600

Categories and tags

Research organisms

Further reading

    1. Cancer Biology
    2. Cell Biology

    mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3IBTK-mediated ubiquitination of eIF4A1 in cancer cells

    Dongyue Jiao, Huiru Sun ... Kun Gao
    Research Article

    Enhanced protein synthesis is a crucial molecular mechanism that allows cancer cells to survive, proliferate, metastasize, and develop resistance to anti-cancer treatments, and often arises as a consequence of increased signaling flux channeled to mRNA-bearing eukaryotic initiation factor 4F (eIF4F). However, the post-translational regulation of eIF4A1, an ATP-dependent RNA helicase and subunit of the eIF4F complex, is still poorly understood. Here, we demonstrate that IBTK, a substrate-binding adaptor of the Cullin 3-RING ubiquitin ligase (CRL3) complex, interacts with eIF4A1. The non-degradative ubiquitination of eIF4A1 catalyzed by the CRL3IBTK complex promotes cap-dependent translational initiation, nascent protein synthesis, oncogene expression, and cervical tumor cell growth both in vivo and in vitro. Moreover, we show that mTORC1 and S6K1, two key regulators of protein synthesis, directly phosphorylate IBTK to augment eIF4A1 ubiquitination and sustained oncogenic translation. This link between the CRL3IBTK complex and the mTORC1/S6K1 signaling pathway, which is frequently dysregulated in cancer, represents a promising target for anti-cancer therapies.

    1. Cancer Biology
    2. Cell Biology

    CYRI-B mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake

    Savvas Nikolaou, Amelie Juin ... Laura M Machesky
    Research Article

    Pancreatic ductal adenocarcinoma carries a dismal prognosis, with high rates of metastasis and few treatment options. Hyperactivation of KRAS in almost all tumours drives RAC1 activation, conferring enhanced migratory and proliferative capacity as well as macropinocytosis. Macropinocytosis is well understood as a nutrient scavenging mechanism, but little is known about its functions in trafficking of signaling receptors. We find that CYRI-B is highly expressed in pancreatic tumours in a mouse model of KRAS and p53-driven pancreatic cancer. Deletion of Cyrib (the gene encoding CYRI-B protein) accelerates tumourigenesis, leading to enhanced ERK and JNK-induced proliferation in precancerous lesions, indicating a potential role as a buffer of RAC1 hyperactivation in early stages. However, as disease progresses, loss of CYRI-B inhibits metastasis. CYRI-B depleted tumour cells show reduced chemotactic responses to lysophosphatidic acid, a major driver of tumour spread, due to impaired macropinocytic uptake of the lysophosphatidic acid receptor-1. Overall, we implicate CYRI-B as a mediator of growth and signaling in pancreatic cancer, providing new insights into pathways controlling metastasis.

    1. Cancer Biology
    2. Cell Biology

    Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics

    Timothy J Walker, Eduardo Reyes-Alvarez ... Lois M Mulligan
    Research Article

    Internalization from the cell membrane and endosomal trafficking of receptor tyrosine kinases (RTKs) are important regulators of signaling in normal cells that can frequently be disrupted in cancer. The adrenal tumor pheochromocytoma (PCC) can be caused by activating mutations of the rearranged during transfection (RET) receptor tyrosine kinase, or inactivation of TMEM127, a transmembrane tumor suppressor implicated in trafficking of endosomal cargos. However, the role of aberrant receptor trafficking in PCC is not well understood. Here, we show that loss of TMEM127 causes wildtype RET protein accumulation on the cell surface, where increased receptor density facilitates constitutive ligand-independent activity and downstream signaling, driving cell proliferation. Loss of TMEM127 altered normal cell membrane organization and recruitment and stabilization of membrane protein complexes, impaired assembly, and maturation of clathrin-coated pits, and reduced internalization and degradation of cell surface RET. In addition to RTKs, TMEM127 depletion also promoted surface accumulation of several other transmembrane proteins, suggesting it may cause global defects in surface protein activity and function. Together, our data identify TMEM127 as an important determinant of membrane organization including membrane protein diffusability and protein complex assembly and provide a novel paradigm for oncogenesis in PCC where altered membrane dynamics promotes cell surface accumulation and constitutive activity of growth factor receptors to drive aberrant signaling and promote transformation.